Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

Diabetologia

Volumn 60, Issue 8, 2017, Pages 1390-1399

  Kapitza, Christoph ^a   Dahl, Kirsten ^b   Jacobsen, Jacob B ^b   Axelsen, Mads B ^b   Flint, Anne ^b  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Beta cell function; Glycaemic control; Placebo controlled trial; Semaglutide; Type 2 diabetes

Indexed keywords

ARGININE; C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ANGINA PECTORIS; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; VOMITING; ADOLESCENT; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; METFORMIN; MIDDLE AGED; PREGNANCY; YOUNG ADULT;

EID: 85019618614     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4289-0     Document Type: Article

References (39)

1. Halban PA, Polonsky KS, Bowden DW et al (2014) Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 37:1751–1758
2. UK Prospective Diabetes Study Group (1995) U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258
3. Garber AJ (2011) Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care 34:S258–S263
4. Portha B, Tourrel-Cuzin C, Movassat J (2011) Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res 2011:376509
5. Wysham C, Blevins T, Arakaki R et al (2014) Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 37:2159–2167
6. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R (2013) Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 36:2543–2550
7. Vilsbøll T, Brock B, Perrild H et al (2008) Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 25:152–156
8. Kondo Y, Satoh S, Osada UN, Terauchi Y (2015) Early liraglutide treatment improves beta-cell function in patients with type 2 diabetes: a retrospective cohort study. Endocr J 62:971–980
9. Degn KB, Juhl CB, Sturis J et al (2004) One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187–1194
10. Zinman B, Gerich J, Buse JB et al (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224–1230
11. Chang AM, Jakobsen G, Sturis J et al (2003) The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52:1786–1791
12. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ (2010) The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59:1765–1770
13. Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515–520
14. Hjerpsted J, Brooks A, Flint A, Kvist T, Blundell J (2016) Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. American Diabetes Association 76th Scientific Sessions, New Orleans, LA, USA, 10–14 June, 2016. Abstract 1046-P
15. Marathe CS, Rayner CK, Jones KL, Horowitz M (2013) Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36:1396–1405
16. Lau J, Bloch P, Schaffer L et al (2015) Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58:7370–7380
17. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A (2015) Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 55:497–504
18. European Agency for the Evaluation of Medicinal Products. International Conference on Harmonisation—World Health Organization Guideline for good clinical practice ICH Harmonised tripartite guideline good clinical practice www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed 10 February 2017
19. World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194
20. American Diabetes Association Workgroup on Hypoglycemia (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28:1245–1249
21. Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377
22. Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Prog Biomed 50:253–264
23. Nauck MA, Petrie JR, Sesti G et al (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39:231–241
24. Kozawa J, Inoue K, Iwamoto R et al (2012) Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig 3:294–297
25. Flint A, Kapitza C, Hindsberger C, Zdravkovic M (2011) The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 28:213–226
26. American Diabetes Association (2016) Standards of medical care in diabetes-2016 abridged for primary care providers. Clin Diabetes 34:3–21
27. Ho TP, Zhao X, Courville AB et al (2015) Effects of a 12-month moderate weight loss intervention on insulin sensitivity and inflammation status in nondiabetic overweight and obese subjects. Horm Metab Res 47:289–296
28. Murakata Y, Fujimaki T, Yamada Y (2015) Age-related changes in clinical parameters and their associations with common complex diseases. Biomed Rep 3:767–777
29. De Tata V (2014) Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms. Front Endocrinol (Lausanne) 5:138
30. Standl E (2007) The importance of beta-cell management in type 2 diabetes. Int J Clin Pract 61(Suppl 153):10–19
31. Zheng J, Chen T, Zhu Y et al (2015) Liraglutide prevents fast weight gain and beta-cell dysfunction in male catch-up growth rats. Exp Biol Med (Maywood) 240:1165–1176
32. Tudurí E, López M, Diéguez C, Nadal A, Nogueiras R (2016) Glucagon-like peptide 1 analogs and their effects on pancreatic islets. Trends Endocrinol Metab 27:304–318
33. Ahmann AJ, Capehorn M, Charpentier G et al (2016) Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). Diabetologia 59:S76 (Abstract)
34. Madsbad S (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18:317–332
35. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13:394–407
36. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH (2006) Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 82:280–284
37. Diamant M, van Gaal L, Stranks S et al (2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375:2234–2243
38. Marre M, Shaw J, Brändle M et al (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268–278
39. Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84–90